COMBINATION CHEMOTHERAPY OF ADVANCED CHRONIC LYMPHOCYTIC-LEUKEMIA - THE M-2 PROTOCOL (VINCRISTINE, BCNU, CYCLOPHOSPHAMIDE, MELPHALAN, AND PREDNISONE)
- 1 January 1982
- journal article
- research article
- Vol. 60 (5), 1110-1121
Abstract
The M-2 protocol (vincristine, cyclophosphamide, BCNU [1,3-bis-(2-chloroethyl)-1-nitrosourea], melphalan and prednisone) was administered monthly to 63 evaluable patients with advanced chronic lymphocytic leukemia [CLL]. Complete remission [CR] absence of all clinical and bone marrow evidence of leukemia and partial response [PR] (> 50% decrease in organ enlargement and reduction of WBC [white blood cell] count to < 15,000 .times. 106/l) were achieved in 17 and 44%, respectively, for a total response rate of 61%. The median survivals from therapy of patients achieving a CR, PR or no response were 73+, 40 and 14 mo., respectively. The median survival time from onset of treatment for stages II, III and IV disease were 47, 20 and 19 mo., respectively, which was not statistically different from historical controls. When untreated patients are compared to this latter group, a significant survival advantage from diagnosis was found (P = 0.01), stressing the importance of prior therapy as the only unfavorable prognostic factor. Although CR in CLL, as reflected in apparently normal bone marrow B-lymphocyte markers, can be induced with acceptable morbidity, the majority of patients relapse after cessation of therapy. An alternative approach to the M-2 protocol is needed to eradicate the disease.This publication has 38 references indexed in Scilit:
- Pulmonary Toxicity Associated with Bischloroethylnitrosourea (BCNU)Annals of Internal Medicine, 1979
- The Spectrum of Drug-Induced Pulmonary DiseaseAnnals of Internal Medicine, 1972
- Chronic Lymphocytic Leukemia With Hemolytic AnemiaArchives of Internal Medicine, 1964
- “Spontaneous” remission in chronic lymphatic leukemia?Cancer, 1964
- VINCRISTINE IN TREATMENT OF LYMPHOMAS AND LEUKEMIAS1963
- Immunologic factors and resistance to infection in chronic lymphatic leukemiaAmerican Journal Of Medicine, 1961
- The Use of Chlorambucil and Steroids in the Treatment of Chronic Lymphocytic LeukaemiaBritish Journal of Haematology, 1961
- THE CLINICAL IMPLICATIONS OF HYPOGAMMAGLOBULINEMIA IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND LYMPHOCYTIC LYMPHOSARCOMAAnnals of Internal Medicine, 1959
- CLINICAL USE OF METHYLPREDNISOLONE IN CERTAIN HEMATOLOGIC DISORDERS1958
- USE OF PITUITARY ADRENOCORTICOTROPIC HORMONE (ACTH) AND CORTISONE IN LYMPHOMAS AND LEUKEMIASJAMA, 1950